Reduceren van de4 kosten van de controle van patienten met niet-spier-invasief blaaskanker

Reducing costs of surveillance of patients with non-muscle invasive bladder cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON28752

Enrollment

450

Registered

2017-12-07

Start date

2015-01-05

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bladder Cancer bladder cancer, non-muscle invasive, surveillance, cystoscopy, urine test Blaaskanker, oppervlakkig blaaskanker, controles, cystoscopie, urine test

Interventions

Cystoscopy is an invasive diagnostic procedure. Urine analysis can replace part of the cystoscopies.

Eligibility

Inclusion criteria

Inclusion criteria: patients under surveillance for recurrences after a NMIBC primary tumor

Exclusion criteria

Exclusion criteria: under 21 years of age patients upgraded at reTUR to NMIBC Patients presenting with MIBC

Design outcomes

Primary

Measure	Time frame
15% extra recurrences detected in maximal care arm; 40% percentage decrease in cystoscopies in optimal care arm; costs of optimal care vs classic care: 4000 euro less;	—

Secondary

Measure	Time frame
lower stage recurrences in high-risk group	—

Contacts

Public ContactE.C. Zwarthoff

e.zwarthoff@erasmusmc.nl

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)